Rami Khouzam, MD
Interventional Cardiology · Myrtle Beach, SCNPI 1255361986
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 41.4% of the total. Reporting peaked in 2019 at $6,454 and has fallen 88.5% since, to $744 in 2025.
Across 171 payments — averaging $91.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$6K
- Penumbra, Inc.$4K
- Medtronic$1K
- Shockwave Medical, Inc$751
- Boston Scientific$649
- AstraZeneca$358
- plus $2K from 23 others
Across 13 payments — averaging $5548.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$53K
- AstraZeneca$15K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Speaking & faculty fees$5,70036%
- Travel & lodging$2,93219%
- Food & beverage$7,03745%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 9 | $6,498 |
| Penumbra, Inc. | 16 | $4,099 |
| Medtronic(2 entities) | 60 | $1,038 |
| Shockwave Medical, Inc | 26 | $751 |
| Boston Scientific | 11 | $649 |
| AstraZeneca(2 entities) | 5 | $358 |
| Abiomed | 2 | $275 |
| Celonova Biosciences, Inc. | 2 | $260 |
| Chiesi USA, Inc. | 2 | $225 |
| BD | 1 | $169 |
| Cardiovascular Systems Inc. | 3 | $163 |
| Recor Medical Inc | 1 | $122 |
| Philips North America LLC | 2 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $110 |
| EKOS Corporation | 1 | $105 |
| E.r. Squibb & Sons, L.L.C. | 2 | $96 |
| Abbott | 3 | $89 |
| Novartis | 5 | $89 |
| Opsens Inc. | 1 | $86 |
| Pfizer | 5 | $82 |
| Atricure, Inc. | 2 | $74 |
| Amgen | 3 | $54 |
| Intact Vascular, Inc. | 1 | $46 |
| Livanova USA, Inc. | 1 | $32 |
| Boehringer Ingelheim | 1 | $25 |
| Avinger Inc. | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUTONIX$5,827
- Indigo System$3,979
- Crosser iQ$461
- AVVIGO Guidance System$300
- Impella$275
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$233
- KENGREAL$225
- RotarexS 6 F x 135 cm$169
- Diamondback Coronary$141
- RESOLUTE ONYX$133
- Vascular Lithotripsy$129
- Paradise Ultrasound Renal Denervation System$122
- ONYX FRONTIER$115
- ANDEXXA$111
- EKOSONIC$105
- FARXIGA$101
- GENERAL - STRUCTURAL HEART$100
How this compares
$15,688 in reported general payments places this provider in the 70th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $253,905 |
| EntrestoSacubitril/Valsartan | 127 | $145,969 |
| FarxigaDapagliflozin Propanediol | 102 | $114,923 |
| XareltoRivaroxaban | 26 | $34,367 |
| Metoprolol Succinate | 314 | $5,682 |
| ClopidogrelClopidogrel Bisulfate | 208 | $2,507 |
| Prasugrel Hcl | 26 | $1,696 |
| Losartan Potassium | 182 | $1,651 |
| Atorvastatin Calcium | 144 | $1,612 |
| Carvedilol | 151 | $1,530 |
| Metoprolol Tartrate | 135 | $1,079 |
| Bumetanide | 23 | $1,064 |
| Rosuvastatin Calcium | 81 | $992 |
| Furosemide | 209 | $830 |
| Amiodarone Hcl | 24 | $732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $253,905195 claims |
| NovartisEntresto | $89 | $145,969127 claims |
| AstraZenecaFarxiga | $358 | $114,923102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Myrtle Beach
- Thuy RyanMyrtle Beach$57K
- James HadstateMyrtle Beach$12K
- Carson KeckMyrtle Beach$10K
- Daniel SteinbergCharleston$611K
- Brian BrownSpartanburg$389K
- Nicholas AmorosoPawleys Island$283K
- Robert LeonardiWest Columbia$203K
- Anbukarasi MaranCharleston$132K
- Jesse JorgensenGreenville$102K
- Thomas TodoranPawleys Island$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.